Chardan Raises Price Target on Editas Medicine

Chardan Raises Price Target on Editas Medicine

Editas Medicine received a price-target increase Thursday from Chardan Capital Markets after the genome-editing company announced late Wednesday the achievement of a second milestone under its collaboration with Juno Therapeutics (JUNO) amid technical progress toward overcoming the tumor microenvironment in a research program. The new price target from Chardan is $72.50, up from $65. This is well above the stock’s Wednesday closing price of $17.98 each. Chardan maintained its investment […]

Read More ˃